AREA PRESCRIBING COMMITTEE – Birmingham, Sandwell, Solihull and environs

Decision Making Support Tool

The following document supports the committee to consider formulary applications against defined criteria.

Formulary application reference:		APCBSSE/0066
Drug name and formulations:		Invicorp® injection (Aviptadil 25mcg / phentolamine 2mg)
Criteria	***Example***	**Committee Consensus**
Patient Safety	*Potential for abuse, toxicity, significant drug interactions*	Similar to alprostadil, claims of less painful injection but evidence provided questionable.
Clinical effectiveness	*Established licensed product*	Non-inferior to alprostadil
Strength of evidence		Weak comparative evidence against intracavernosal injection.
Cost effectiveness or resource impact	*£*	Currently cost neutral vs alprostadil injection but ongoing supply issues with alprostadil.
Place of therapy relative to available treatments	*1/2nd tier*	3rd line after PDE5 inhibitors and alprostadil
National guidance and priorities	*NICE, MTRAC*	British Society for Sexual Medicine (BSSM) guidelines 2008
Local health priorities	*CCG views*	CCGs would support
Equity of access	*Equality assessment*	N/A
Stakeholder views	*Define wider groups to be engaged*	N/A
Implementation requirements	*Requires, RICAD ESCA etc.*	N/A

Decision Summary

Resubmission is recommended to complete the information to enable a decision:	
Not approved and rationale:	
Formulary status (RAG) and rationale	AMBER, Specialist initiation. 3rd line after oral PDE5 inhibitors failed and patient not responding to or intolerant of alprostadil. To be reviewed within 12 months to assess alprostadil injection supply issues and patent expiry. Rationale: supply issues and awaiting the BSSM guidelines.
Implementation requirements:	
Implementation monitoring:	